Regeneron Pharmaceuticals Net Worth
Regeneron Pharmaceuticals Net Worth Breakdown | REGN |
Regeneron Pharmaceuticals Net Worth Analysis
Regeneron Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Regeneron Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Regeneron Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Regeneron Pharmaceuticals' net worth analysis. One common approach is to calculate Regeneron Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Regeneron Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Regeneron Pharmaceuticals' net worth. This approach calculates the present value of Regeneron Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Regeneron Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Regeneron Pharmaceuticals' net worth. This involves comparing Regeneron Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Regeneron Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Regeneron Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Regeneron Pharmaceuticals' net worth research are outlined below:
| Regeneron Pharmaceuticals generated a negative expected return over the last 90 days | |
| Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: BioFuture 2024 Wraps Up Hundreds of High-Profile Attendees Joined Record Numbers of Investors and Media |
Regeneron Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Regeneron Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Regeneron Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 2nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Regeneron Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Regeneron Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regeneron Pharmaceuticals backward and forwards among themselves. Regeneron Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Regeneron Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Loomis, Sayles & Company Lp | 2024-06-30 | 1.2 M | Norges Bank | 2024-06-30 | 1.1 M | Amundi | 2024-06-30 | 1.1 M | Wellington Management Company Llp | 2024-06-30 | 1.1 M | Legal & General Group Plc | 2024-06-30 | 978.1 K | Bank Of America Corp | 2024-06-30 | 968.1 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 932.9 K | Northern Trust Corp | 2024-09-30 | 918.6 K | Amvescap Plc. | 2024-06-30 | 916.4 K | Fmr Inc | 2024-09-30 | 10.4 M | Vanguard Group Inc | 2024-09-30 | 9.3 M |
Follow Regeneron Pharmaceuticals' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 81.1 B.Market Cap |
|
Project Regeneron Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.12 | 0.13 | |
| Return On Capital Employed | 0.14 | 0.14 | |
| Return On Assets | 0.12 | 0.13 | |
| Return On Equity | 0.15 | 0.16 |
When accessing Regeneron Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Regeneron Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Regeneron Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Regeneron Pharmaceuticals' management efficiency
Regeneron Pharmaceuticals has return on total asset (ROA) of 0.0741 % which means that it generated a profit of $0.0741 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1717 %, meaning that it created $0.1717 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals' management efficiency ratios could be used to measure how well Regeneron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to 0.13. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Regeneron Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to 0.13, while Other Current Assets are likely to drop about 197.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 243.42 | 255.59 | |
| Tangible Book Value Per Share | 233.69 | 245.37 | |
| Enterprise Value Over EBITDA | 20.13 | 21.14 | |
| Price Book Value Ratio | 3.61 | 5.22 | |
| Enterprise Value Multiple | 20.13 | 21.14 | |
| Price Fair Value | 3.61 | 5.22 | |
| Enterprise Value | 38.4 B | 40.3 B |
At Regeneron Pharmaceuticals, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 5.3445 | Revenue 13.8 B | Quarterly Revenue Growth 0.106 | Revenue Per Share 128.691 | Return On Equity 0.1717 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regeneron Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regeneron Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regeneron Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Andrew Murphy over six months ago Disposition of tradable shares by Andrew Murphy of Regeneron Pharmaceuticals at 962.87 subject to Rule 16b-3 | ||
Arthur Ryan over six months ago Disposition of tradable shares by Arthur Ryan of Regeneron Pharmaceuticals at 986.58 subject to Rule 16b-3 | ||
Huda Zoghbi over a year ago Exercise or conversion by Huda Zoghbi of 1000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 | ||
Huda Zoghbi over a year ago Exercise or conversion by Huda Zoghbi of 1706 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 | ||
Huda Zoghbi over a year ago Exercise or conversion by Huda Zoghbi of 1706 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 |
Regeneron Pharmaceuticals Corporate Filings
F4 | 12th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Regeneron Pharmaceuticals Earnings per Share Projection vs Actual
Regeneron Pharmaceuticals Corporate Management
| Joseph JD | General VP | Profile | |
| Patrice Gilooly | Senior Operations | Profile | |
| Andrew Murphy | Executive Research | Profile | |
| Christopher CPA | Head Finance | Profile | |
| Bob McCowan | Senior Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.298 | Earnings Share 40.44 | Revenue Per Share 128.691 | Quarterly Revenue Growth 0.106 | Return On Assets 0.0741 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.